SCHEMBL6035137

SCHEMBL6035137

Cc1nn(-c2ccc(C(F)(F)F)cn2)cc1CCCOc1cc(CC(=O)O)n(C)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.36
HPGD P15428 1/20 0.36
PKM P14618 1/20 0.36
AGBL2 Q5U5Z8 1/20 0.35
MAPT P10636 2/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
PPARD Q03181 3/20 0.34
PPARA Q07869 2/20 0.34
PPARG P37231 1/20 0.34
GCGR P47871 2/20 0.33
EGLN1 Q9GZT9 1/20 0.33
POLB P06746 1/20 0.33
PTGDR2 Q9Y5Y4 2/20 0.33
CHRNA7 P36544 1/20 0.33
HDAC4 P56524 1/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
HTT P42858 2/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6036044 0.89 SMN1; SMN2 (0.37) SMN1; SMN2HPGDPKMMAPTNPC1
SCHEMBL6034860 0.85 SMN1; SMN2 (0.38) SMN1; SMN2HPGDPKMAGBL2MAPT
SCHEMBL6035450 0.83 FFAR1 (0.37) SMN1; SMN2HPGDPKMMAPTNPC1
SCHEMBL6034689 0.83 PPARD (0.36) SMN1; SMN2HPGDMAPTNPC1RAB9A
SCHEMBL6036397 0.82 GCGR (0.36) SMN1; SMN2HPGDPKMPPARDGCGR
SCHEMBL6035943 0.82 GCGR (0.38) SMN1; SMN2HPGDPKMMAPTNPC1
SCHEMBL6035777 0.82 SMN1; SMN2 (0.37) SMN1; SMN2HPGDPKMMAPTNPC1
SCHEMBL6035912 0.81 PPARD (0.44) SMN1; SMN2HPGDMAPTPPARDPPARA
SCHEMBL6035650 0.81 PLA2G4B (0.39) SMN1; SMN2MAPTPPARDPPARAPPARG
SCHEMBL6036332 0.79 GCGR (0.36) SMN1; SMN2HPGDPKMPPARDGCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 SMN1; SMN2 4408/4885HPGD 3297/4885PKM 2082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.